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Demographic associations 
for autoantibodies in disease-
free individuals of a European 
population
Kadri Haller-Kikkatalo1,2,3,*, Kristi Alnek1,*, Andres Metspalu4,5, Evelin Mihailov4, 
Kaja Metsküla1, Kalle Kisand1, Heti Pisarev6, Andres Salumets2,3,7,8 & Raivo Uibo1,2
The presence of autoantibodies usually precedes autoimmune disease, but is sometimes considered an 
incidental finding with no clinical relevance. The prevalence of immune-mediated diseases was studied 
in a group of individuals from the Estonian Genome Project (n = 51,862), and 6 clinically significant 
autoantibodies were detected in a subgroup of 994 (auto)immune-mediated disease-free individuals. 
The overall prevalence of individuals with immune-mediated diseases in the primary cohort was 30.1%. 
Similarly, 23.6% of the participants in the disease-free subgroup were seropositive for at least one 
autoantibody. Several phenotypic parameters were associated with autoantibodies. The results suggest 
that (i) immune-mediated diseases are diagnosed in nearly one-third of a random European population, 
(ii) 6 common autoantibodies are detectable in almost one-third of individuals without diagnosed 
autoimmune diseases, (iii) tissue non-specific autoantibodies, especially at high levels, may reflect 
preclinical disease in symptom-free individuals, and (iv) the incidental positivity of anti-TPO in men with 
positive familial anamnesis of maternal autoimmune disease deserves further medical attention. These 
results encourage physicians to evaluate autoantibodies in addition to treating a variety of patient 
health complaints to detect autoimmune-mediated disease early.
Autoantibodies are immunoglobulins (Ig) produced by activated autoreactive B cells. The immune response 
towards self-antigens usually involves activation of both T and B cells, but the detection of autoantibodies in sera 
is technically simpler than detection of T-cell reactions. Therefore, autoantibodies can be used to guide clinical 
management of certain diseases. These markers of disease activity and severity help to define and classify diseases 
and can be used to predict and diagnose specific autoimmune diseases1.
Autoimmune diseases affect at least 5% of the population1, while the prevalence of diseases that involve 
immune reactions, including connective tissue diseases (CTD) and diseases with hypersensitivity reactions, 
is much higher2. In reality, the actual burden of various (auto)immune reactions in different populations is 
unknown.
Some autoantibodies are functional and are therefore considered clinically significant, while the others are 
bystanders in disease pathogenesis (or their function has not yet been discovered). For example, IgG-type autoan-
tibodies to the 100 kDa membrane bound glycoprotein thyroid peroxidase (anti-TPO) interrupt the production 
of thyroid hormones and cause autoimmune hypothyroiditis3. In addition, anti-TPO IgGs have been detected 
in cases of Graves’ disease and postpartum thyroid dysfunction, but they have also been detected in control 
individuals without thyroid disease1. Therefore, anti-TPO represents an autoantibody with tissue-specificity 
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and clinical significance unspecific to thyroiditis. On the contrary to tissue-specific autoantibodies which are 
produced against antigens expressed in single tissue, tissue non-specific antigens recognise antigens expressed 
ubiquitously or at least in several tissues. IgA-type autoantibodies against the 78 kDa tissue transglutaminase 
(anti-tTG) are highly specific to coeliac disease4, making them clinically significant but not tissue specific. 
Although tTG belongs to a family of multifunctional transglutaminases, in coeliac disease, the anti-tTG IgAs 
produced in the small-intestinal mucosa interrupt the conversion of a glutamine residue into glutamic acid dur-
ing gluten digestion5.
Depending on the disease, time of testing, and the number and detection level of autoantibodies, the sensi-
tivity of predicting autoimmune disease is rarely 100%1. In other words, there are always individuals who test 
positive for autoantibodies but have no clinical signs of autoimmune disease for years. Similarly, there are cases 
where autoimmune disease develops without prior clinical indication. Therefore, the interpretation of positive 
autoantibody tests can be challenging in diseases such as thyroiditis, as anti-thyroid autoantibodies may precede 
disease manifestation by two decades, and some individuals (10%) stay disease-free despite the presence of 
autoantibodies6. Data interpretation is further complicated in diseases with complex pathologies, such as CTD, 
an autoimmune-inflammatory disease7. Furthermore, autoantibodies may be produced temporarily to facilitate 
communication between immune cells and molecules or between immune cells and other tissues, particularly 
during immune challenges such as viral infections8.
The prevalence and relevance of autoantibodies in healthy individuals are poorly studied, and most data found 
in the literature are derived from assessing autoantibodies in patients with autoimmune diseases1,4. Two outstand-
ing questions that remain unanswered are how often autoantibodies can be detected in clinically healthy individ-
uals and whether the presence of autoantibodies predicts the future onset of autoimmune disease. A prospective 
follow-up survey of selected individuals would be the gold standard to study these questions6, but needs highly 
synchronized medical efforts for organizing such studies and significant financial resources.
In this study, we aimed to determine the prevalence of selected clinically significant autoantibodies in (auto)
immune-mediated disease-free individuals and to carry out an association study to explain the existence of 
autoantibodies in these healthy individuals. Namely, the data from a population-based registry of 51,862 adults 
from the Estonian Genome Center at the University of Tartu, Estonia (EGCUT) was used to assess (auto)
immune-mediated diseases in the general population of Estonia. The study group of healthy individuals repre-
sentative of the population was randomly selected from that registry. Study individuals were tested for anti-TPO 
IgG and 5 tissue non-specific autoantibodies diagnostic of major (auto)immune-mediated diseases. The presence 
of autoantibodies was assessed in relation to phenotypic characteristics in disease-free individuals.
Materials and Methods
Study population. This cross-sectional study comprised 994 individuals who lacked autoimmune or other 
immune-mediated diseases. Participants were selected from the 51,862 individuals aged 18 years or older in the 
EGCUT biopank, which is a population-based biopank compiled from 2002 to 2014 (www.biobank.ee)9. All study 
protocols were conducted in accordance with the Estonian Gene Research Act.
The EGCUT cohort closely reflected the age, sex, and geographical distribution of the Estonian population9, 
and all subjects were recruited voluntarily and randomly by general practitioners and hospital physicians. A 
computer-assisted personal interview, which included personal, genealogical, educational and occupational his-
tory, and lifestyle data, was completed. Anthropometric measurements, blood pressure, and resting heart rate 
were measured, and venous blood was drawn during the visit. Medical history and current health status were 
recorded according to International Classification of Diseases -10 (ICD-10) codes. The individuals excluded from 
the study of diagnoses with (auto)immune-mediated diseases are listed in Supplementary Table S.1. Random 
selection of the individuals representative of the age and gender distribution in the Estonian population resulted 
in 1,000 individuals. However, following a secondary survey of medical records of these 1,000 individuals, an 
additional 6 individuals possessing at least one of the (auto)immune-mediated diseases were excluded from the 
study group. Thus, the total number of study participants was 994 (491 men and 503 women ranging from 18 to 
86 years old). Phenotypic characteristics and ethylenediaminetetraacetic-acid-treated (EDTA) plasma samples 
from each individual were used. Each participant signed an informed consent prior to enrolment, and ethical 
approval for the study was obtained from the Ethics Review Committee on Human Research at the University of 
Tartu.
Phenotypic data, including socio-demographic data, smoking and alcohol consumption, medication use, 
parents’ diseases, and female reproductive health-related data were used. Socio-demographic data consisted 
of age at agreement (age at time of study), nationality, city or rural residence at birth, occupation, and body 
mass index (BMI). Medication data consisted of medications that were used on a regular basis for the last two 
months. Medications were classified according to the Anatomical Therapeutic Chemical Classification System 
level. A study participant was considered to be using a hazardous drug if he/she used a medication associated with 
drug-induced lupus as described in Chang et al.10.
Antibody tests. All participants were tested for anti-TPO and 5 tissue non-specific autoantibodies - anti-
nuclear antibodies (ANA), which were measured with CTD IgG screening test (anti-CTD), anti-tTG IgA and 
IgG, cyclic citrullinated peptide IgG (anti-CCP), and antibodies of all isotypes against glutamic acid decarbox-
ylase with molecular weight of 65 kDa (GADA). Anti-CTD was further specified with the eight most common 
IgG-type autoantibodies: antibodies against double-stranded deoxyribonucleic acid (anti-dsDNA), Sjögren’s 
syndrome type A antigen (anti-SS-A/Ro) protein, Sjögren’s syndrome type B antigen (anti-SS-B/La) protein, cen-
tromere protein (anti-CENP), histidyl-tRNA synthetase (anti-Jo-1) protein, scleroderma-associated autoantigen 
of 70 kDa (anti-Scl-70) protein, Smith (anti-Sm) protein, and ribonucleoprotein U1 (anti-U1RNP) protein.
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GADA were measured with commercial enzyme-linked immunosorbent assay (ELISA) kit (RSR Ltd., Cardiff, 
UK). Plasma from EDTA-vacutainers was treated with calcium11. According to the manufacturer’s instructions, 
values 5 U/ml or grater were considered positive.
Anti-TPO, anti-CCP, anti-tTG IgA and IgG, anti-CTD, and autoantibodies from CTD tests were analysed 
with a fully automated fluoro-enzyme immunoassay (FEIA) on an ImmunoCAP 100 (Phadia, Thermo Scientific 
Corporation, Vantaa, Finland). Positive cut-off values were chosen according to the manufacturer’s recommenda-
tions: ≥ 100 IU/ml for anti-TPO, ≥ 10 U/ml for anti-CCP, ≥ 10 U/ml for anti-tTG, and an autoantibody ratio ≥ 1.0 
for anti-CTD. To specify anti-CTD, all positive and grey zone (0.7–1.0) test results were reassessed with the eight 
most common ANAs: anti-dsDNA, anti-SS-A/Ro, anti-SS-B/La, anti-CENP, anti-Jo-1, anti-Scl-70, anti-Sm, and 
anti-U1RNP IgG. Anti-dsDNA values 15 IU/ml or more were considered positive, while the cut-off value for the 
remaining 7 autoantibodies was set to 10 U/ml, according to the manufacturer’s instructions.
Statistical analyses. The Welch Two Sample t-test and Proportion test with continuity correction were used 
to compare the reported phenotypic characteristics and prevalence of autoantibodies between men and women, 
and p values < 0.05 were considered significant. Multiple logistic regression analyses adjusted for age and strat-
ified by gender were used to find associations between the presence of autoantibodies and phenotypic data. For 
association analyses, autoantibodies were considered binomial variables for logistic regression – (i) the presence 
of anti-TPO IgG as a tissue-specific autoantibody and (ii) the presence of at least one of the 5 tissue non-specific 
autoantibodies: GADA, anti-CCP IgG, anti-tTG IgG and IgA, or anti-CTD IgG. The age at time of study was 
considered a continuous variable, and a categorical variable of age groups was formed based on the values of the 
first and third quantiles and median age and compared with the youngest group (18–26 years). Adjusted odds 
ratios (adORs) were calculated, and corrected p values < 0.05 were considered statistically significant, while cor-
rected p values > 0.05 and < 0.1 were considered tendencies for a significant association. The R3.1.0 Language and 
Environment was used for statistical analyses.
The data set supporting the results of this article is included within the article and it’s Supplementary Table.
Results
Health parameters of the study population. According to data registered by EGCUT by May 2014, 
approximately 30% of the adult population in Estonia has been diagnosed with some type of (auto)immune-me-
diated disease (Supplementary Table S.1). As expected, women were diagnosed more frequently than men (32.1% 
vs. 26.4%), except in the case of insulin-dependent (type 1) diabetes, which occurred more frequently among men 
(0.5%) than women (0.3%, Table 1). Coeliac disease was diagnosed very rarely in the population (0.04%), and the 
frequency was not different in men and women. More important in the context of the current study is the fact 
that 2/3 of the adult population was registered healthy and free from (auto)immune-mediated diseases at the time 
of recruitment into the EGCUT registry and formed the basis for the selection of our study group – 994 (auto)
immune disease-free individuals representative of the entire Estonian population of adults in the distribution of 
age and gender.
The patient characteristics and health parameters of the study group (994 individuals) are provided in Table 2. 
The mean age of the participants was 39.9 years. The study population also contained approximately equal num-
bers of men and women who originated from the city or the countryside. The prevalence of employment and 
student status was similar between genders, but more men were retired, and more women were unemployed due 
to reasons other than retirement. Smoking was greater among men. Men also started smoking at younger ages. 
If men did consume alcohol, they did it more frequently than women. Seventy-three percent of women reported 
that they had been pregnant, and 68% of all women had at least one child. More women in the study population 
were normal weight than men, who were more often overweight. The prevalence of both extremes, underweight 
(BMI < 18.5 kg/m2) and obesity (BMI ≥ 30 kg/m2), were similar between genders. Regular medication use in the 
most recent 2 months was also similar between men and women. The prevalence of individuals taking drug(s) 
Disease category ICD-102 category or subcategory
% (95% confidence interval)
Men N = 17,821
Women 
N = 34,041 Total N = 51,862
Hypo-, hyperthyroidism or 
thyroiditis
E03.4, E03.5, E03.8, E03.9, E05.0, 
E05.9, E06.2, E06.3 0.5% (0.4–0.6) 3.1% (2.9–3.3) 2.2% (2.1–2.3)
Coeliac disease K90.0 0.04% (0.02–0.08) 0.05% (0.03–0.08) 0.04% (0.03–0.07)
Rheumatoid arthritis
M05.0, M05.1, M05.3, M05.4, M05.8, 
M05.9, M06.0, M06.1, M06.2, M06.3, 
M06.4, M06.8, M06.9
0.6% (0.5–0.7) 1.9% (1.7–2.0) 1.4% (1.3–1.5)
Insulin-dependent (type 1) diabetes 
mellitus E10 0.5% (0.4–0.6) 0.3% (0.2–0.3) 0.4% (0.3–0.4)
Other diabetes mellitus E11-14 5.4% (5.1–5.8) 4.5% (4.3–4.7) 4.8% (4.6–5.0)
Diseases of the skin, subcutaneous 
tissue, musculoskeletal system and 
connective tissue 
L40, L63, L80, L93, M05-09, M12, 
M30-36, M45, M46 5.3% (5.0–5.7) 7.1% (6.8–7.4) 6.5% (6.3–6.7)
Total1 26.4% (25.7–27.0) 32.1% (31.6–32.6) 30.1% (29.7–30.5)
Table 1.  Prevalence of common (auto)immune-mediated diseases in Estonian adults. 1Includes all immune 
mediated diseases listed in Supplementary Table S.1. The prevalence in each gender was compared with the 
Proportion test. Bold indicates p < 0.05. 2ICD-10 − International Classification of Diseases-10
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Characteristics1 Men (n = 491) Women (n = 503) Total (n = 994)
Age at time of study (yr) 39.8 ± 16.5 39.9 ± 16.1 39.9 ± 16.3
Place of birth
 City 302 (63.2%, 58.7–67.5) 310 (64.2%, 59.7–68.4) 612 (63.7%, 60.5–66.7)
 Countryside 176 (36.8%, 32.5–41.3) 173 (35.8%, 31.6–40.3) 349 (36.3%, 33.3–39.5)
Occupation
 Employed 320 (66.8%, 62.4–71.0) 330 (68.3%, 63.9–72.4) 650 (67.6%, 64.5–70.5)
 Pension insurance2 43 (9.0%, 6.6–12.0) 28 (5.8%, 4.0–8.4) 71 (7.4%, 5.8–9.3)
 Student or serviceman 56 (11.7%, 9.0–15.0) 46 (9.5%, 7.1–12.6) 102 (10.6%, 8.8–12.8)
 Unemployed3 60 (12.5%, 9.8–15.9) 79 (16.4%, 13.2–20.0) 139 (14.4%, 12.3–16.9)
Smoking status
 Never smoker 230 (46.8%, 42.4–51.4) 312 (62.0%, 57.6–66.3) 542 (54.5%, 51.4–57.6)
 Former smoker 89 (18.1%, 14.9–21.9) 50 (9.9%, 7.5–13.0) 139 (14.0%, 11.9–16.3)
 Current smoker 172 (35.0%, 30.8–39.5) 142 (28.2%, 24.4–32.4) 313 (31.5%, 28.6–34.5)
Frequency of alcohol consumption
 Rare – up to few times a year 32 (9.9%, 7.0–13.8) 67 (21.3%, 17.0–26.3) 99 (15.5%, 12.8–18.6)
 Seldom – up to every month 48 (14.8%, 11.2–19.3) 74 (23.5%, 19.0–28.6) 122 (19.1%, 16.2–22.4)
 Moderate or frequent – up to every 2nd day 244 (75.3%, 70.2–79.8) 174 (55.2%, 49.6–60.8) 418 (65.4%, 61.6–69.1)
Age when started smoking (yr) 18.0 ± 4.0 20.6 ± 6.5 19.7 ± 5.4
Has been pregnant — 365 (72.6%, 68.4–76.4) —
Age at first pregnancy (yr) — 22.0 ± 3.8 —
Live birth(s)
 No children — 138 (27.4%, 23.6–31.6) —
 1 97 (19.3%, 16.0–23.1)
 2 — 158 (31.4%, 27.4–35.7)
 ≥ 3 89 (17.7%, 14.5–21.4)
Active ovarian hormones4 — 349 (69.7%, 65.4–73.6) —
Body mass index (kg/m2)
 Normal 18.5–24.9 221 (45.0%, 40.6–49.5) 271 (54.0%, 49.5–58.4) 492 (49.5%, 46.4–52.7)
 Underweight < 18.5 8 (1.6%, 0.8–3.3) 16 (3.2%, 1.9–5.2) 24 (2.4%, 1.6–3.6)
 Overweight 25.0–29.9 186 (37.9%, 33.6–42.4) 129 (25.7%, 22.0–29.8) 315 (31.7%, 28.9–34.7)
 Obesity ≥ 30 76 (15.5%, 12.5–19.1) 86 (17.1%, 14.0–20.8) 162 (16.3%, 14.1–18.8)
Recently used drugs5
 Cardiovascular system (C) 82 (16.7%, 13.6–20.4) 77 (15.3%, 12.3–18.8) 159 (16.0%, 13.8–18.5)
 Urogenital tract (G) 6 (1.2%, 0.5–2.8) 7 (1.4%, 0.6–3.0) 13 (1.3%, 0.7–2.3)
 Central nervous system (N) 41 (8.4%, 6.1–11.2) 40 (8.0%, 5.8–10.8) 81 (8.1%, 6.6–10.1)
 Respiratory tract (R) 14 (2.9%, 1.6–4.9) 11 (2.3%, 1.1–4.0) 25 (2.5%, 1.7–3.7)
 Immune system (H, J, L) 16 (3.3%, 1.9–5.4) 25 (5.0%, 3.3–7.4) 41 (4.1%, 3.0–5.6)
 Subgroup of immunity-affecting drugs6 68 (13.8%, 11.0–17.3) 78 (15.5%, 12.5–19.0) 146 (14.7%, 12.6–17.1)
Maternal autoimmune disease7 56 (11.4%, 8.8–14.6) 84 (16.7%, 13.6–20.3) 140 (14.1%, 12.0–16.4)
Paternal autoimmune disease8 62 (12.6%, 9.9–16.0) 39 (7.8%, 5.6–10.5) 101 (10.2%, 8.4–12.2)
Table 2.  Reported phenotypic characteristics of the study population. 1Participants lacking data were 
excluded from this data calculation. 2Pension insurance includes retired persons and unemployed persons 
with insurance for disability. 3Unemployed includes women on childcare leave. 4Women with active ovarian 
hormones includes women who menstruate and women with primary or secondary amenorrhea who are 
currently receiving hormone replacement therapy. 5Drugs used regularly during last 2 months were classified 
according to the Anatomical Therapeutic Chemical Classification System. 6Drugs that increase risk of 
developing lupus or other autoimmune diseases10. 7Participants who reported that their mother had at least 
one of the following autoimmune diseases (ICD-10): thyroiditis (E06), insulin dependent diabetes (E10), 
other adrenal diseases (E27), sclerosis multiplex (G35), sleep disorders (G47), rhinitis (J30), asthma (J45), 
atopic dermatitis (L20), psoriasis (L40), urticaria (L50), vitiligo (L80), arthropathies (M00-25), seropositive 
rheumatoid arthritis (M05), other rheumatoid arthritis (M06), or systemic sclerosis (M34). 8Participants 
who reported that their father had at least one of the following autoimmune diseases (ICD-10): vitamin B12 
deficiency (D51), thyrotoxicosis (E05), insulin-dependent diabetes (E10), sclerosis multiplex (G35), sleep 
disorders (G47), rhinitis (J30), asthma (J45), atopic dermatitis (L20), allergic contact dermatitis (23), psoriasis 
(L40), seropositive rheumatoid arthritis (M05), other rheumatoid arthritis (M06), systemic sclerosis (M34), 
other systemic involvement of connective tissue (M35), ankylosing spondylitis (M45). Statistically significant 
differences (p < 0.05) are shown in bold. Numeric data are provided as means ± standard deviation and were 
compared between men and women with t-test. Non-parametric data are provided as count; the percentage of a 
row and 95% confidence intervals of percentage were compared between genders with a proportion test.
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included in the Anatomical Therapeutic Chemical Classification System or capable of inducing autoimmune 
diseases10, ranged from 1.3–16.0%, and did not differ between men and women. More women than men (16.7% 
vs. 11.4%) reported that their mothers had at least one (auto)immune-mediated disease and men reported more 
frequently same diseases in their father’s (Table 2).
Prevalence of and associations with autoantibodies. The most prevalent autoantibodies detected 
in this study were GADA (8.8%), anti-TPO IgG (7.2%), and anti-CTD (4.8%). The total prevalence of at least 
one autoantibody was 23.6% (Table 3), while the co-existence of two or more autoantibodies was found in 2% of 
participants (95% confidence interval (CI): 0.0–8.0). The prevalence of detected autoantibodies in comparison of 
data from literature is presented in Table 4.
Autoantibodies were divided into two groups for further association analyses according to specificity. 
Anti-TPO IgG was classified as a tissue-specific autoantibody, and the tissue non-specific autoantibodies included 
GADA, anti-CCP IgG, anti-tTG IgG and IgA, and anti-CTD IgG. After adjusting for age and stratifying by gen-
der, linear and logistic regression analyses revealed the phenotypic characteristics that were significantly asso-
ciated with autoantibodies (Table 5). These characteristics were used as adjustments for association analyses of 
autoantibodies.
Multivariate regression model simultaneously controlled for all significant parameters from Table 5 was used 
to calculate corrected p value from multiple comparisons (corrected p value < 0.05 was considered statistically 
significant). These risk factors with the adjusted ORs are shown in Fig. 1. The presence of anti-TPO IgG was 
assessed in the gender-stratified logistic regression model adjusted for age, maternal autoimmune disease, and 
occupational status (significant phenotypic parameters for anti-TPO, Table 5). The analyses revealed that the 
presence of anti-TPO autoantibodies in men was independently associated with (i) the presence of maternal 
autoimmune disease (adOR = 5.51, p = 0.001 compared to men whose mothers were not suffering from auto-
immune diseases), (ii) older age (adOR = 1.05, p = 0.008 for one year of age, data not shown in Fig. 1), and (iii) 
tended to be associated with occupational status of being student or serviceman (adOR = 3.86, p = 0.065). The 
same model for women showed an increased risk of anti-TPO for age group older than 52 years (adOR = 3.54, 
p = 0.014 for ages > 52 years compared to the youngest women of 18–26 years of age) and risk for anti-TPO was 
not increased at younger age groups. The presence of at least one tissue non-specific autoantibody in men was 
assessed in association with the phenotypic parameters of age, frequency of alcohol consumption, and need for 
cardiovascular treatment (significant phenotypic characteristics for current autoantibodies, Table 5). This model 
revealed that the likelihood of having one tissue non-specific autoantibody in men tended to be increased by (i) 
age (adORs for age groups 27–37 years, 38–52 years, and older than 52 years were 2.15, p = 0.072; 2.21, p = 0.059; 
Autoantibodies Population
% (95% confidence intervals)
Men Women Total
n = 491 n = 503 n = 994
(1) Anti-tTG IgA 994 0.0 1.2 (0.5–2.7) 0.6 (0.2–1.4)
(2) Anti-tTG IgG 994 0.0 0.4 (0.1–1.6) 0.2 (0.0–0.8)
(3) Anti-CCP IgG 994 0.0 1.0 (0.4–2.4) 0.5 (0.2–1.2)
(4) Anti-CTD IgG test 994 3.1 (1.8–5.1) 6.6 (4.6–9.2) 4.8 (3.6–6.4)
Anti-dsDNA IgG 851 1.0 (0.4–2.5) 2.2 (1.2–4.0) 1.6 (1.0–2.7)
Anti-SS-B/La IgG 851 0.2 (0.0–1.3) 0.0 0.1 (0.0–0.7)
Anti-SS-A/Ro IgG 851 0.4 (0.1–1.6) 1.0 (0.4–2.4) 0.7 (0.3–1.5)
Anti-Sm IgG 851 0.0 0.0 0.0
Anti-U1RNP IgG 851 0.0 0.2 (0.0–1.3) 0.1 (0.0–0.7)
Anti-CENP IgG 851 0.0 0.6 (0.2–1.9) 0.3 (0.1–1.0)
Anti-Jo-1 IgG 851 0.0 0.0 0.0
Anti-Scl-70 IgG 851 0.0 0.0 0.0
(5) GADA Ig2 994 7.9 (5.8–10.8) 9.5 (7.2–12.5) 8.8 (7.1–10.7)
≥ 1 tissue non-specific autoantibodies3 994 14.7 (11.7–18.2) 19.9 (16.5–23.7) 17.3 (15.0–19.8)
(6) Anti-TPO IgG 994 3.7 (2.3–5.8) 10.7 (8.2–13.9) 7.2 (5.7–9.1)
≥ 1 any autoantibodies4 994 17.7 (14.5–21.5) 29.4 (25.5–33.6) 23.6 (21.1–26.4)
Table 3.  Prevalence of autoantibodies in the study population. 1Antigen-specifying tests were performed on 
participants who were borderline positive for antinuclear autoantibodies, and the test results (prevalence) were 
expanded to entire study population. 2Ca2+-treated peripheral blood plasma. 3Presence of at least one of five 
tissue non-specific autoantibodies. 4Presence of at least one of six measured autoantibodies. Data are provided 
as percentage and 95% CI of percentage and prevalence was compared between genders with a proportion test. 
CCP - cyclic citrullinated peptide, CENP - centromere protein, dsDNA – double-stranded deoxyribonucleic 
acid, GADA - autoantibodies against glutamic acid decarboxylase (molecular weight of 65 kDa), Jo-1 – histidyl-
tRNA synthetase, SS-A/Ro - Sjögren’s syndrome type A antigen, SS-B/La - Sjögren’s syndrome type B antigen, 
Scl-70 - scleroderma-associated autoantigen of 70k Da, Sm - Smith protein, TPO – thyroid peroxidase, tTG 
- tissue transglutaminase, U1RNP - ribonucleoprotein U1. Statistically significant differences (p < 0.05) are 
shown in bold.
www.nature.com/scientificreports/
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Autoantibody
Corresponding disease and its prevalence % 
(95% CI) CommentsName
Prevalence % 
(95% CI) Population Method
Anti-tTG IgA
0.6% (0.2–1.4) Immune-mediated disease-free adults, Estonia FEIA*
Coeliac disease: Reported in 0.04% (0.03–0.07) 
of general population, Estonia34, Estimated 
in 0.5–1.0% of general population, USA, UK, 
and other European countries (for review see 
ref. 35). Estimated in 0.5% (0.2–0.8) of general 
population of adults, Denmark36
According to the prevalence 
and specificity of anti-tTG 
IgA37,38, coeliac disease is clearly 
underdiagnosed at least in Estonia.
0.3% (0.1–0.9) School children, Estonia FEIA34
0.8% General population, Natrona County, USA ELISA
39
Anti-CCP IgG
0.5% (0.2–1.2) Immune-mediated disease-free adults, Estonia FEIA*
Rheumatoid arthritis: 
Reported in 1.4% (1.3–1.5) of general 
population, Estonia,34  
Systemic sclerosis:  
Estimated in 0.024% of general population, 
Australia, Spain, USA (for review see ref. 40)
Logical difference between 
autoantibody-prevalence in 
disease-free individuals and 
two times high prevalence in 
general population. Autoantibody 
prevalence is comparable to 
reported cases of rheumatoid 
arthritis in general population.
1% (0-5) General population, Salt Lake City, Utah, USA ELISA
41
1% General population, Southern Brazil NA42
65% (56–73) Patients with rheumatoid arthritis, Salt Lake City, Utah, USA ELISA
41
11.5% Patients with systemic sclerosis, Southern Brazil NA
42
Anti-CTD IgG: 
4.8% (3.6–6.4) Immune-mediated disease-free adults, Estonia FEIA* Various CTDs: Reported diseases of the skin, subcutaneous tissue, musculoskeletal system 
and connective tissue in 6.5% (6.3–6.7) of 
general population, Estonia34
Antinuclear autoantibodies 
detected by CTD panel have similar 
prevalence in different populations 
and reflect general prevalence of 
CTDs.
< 4% General population, Belgium FEIA20
2.0% General population, Australia ELISA19
 Anti-dsDNA
1.6%(1.0–2.7) Immune-mediated disease-free adults, Estonia FEIA* Lupus erythematosus43: Reported in 0.06% 
(0.05–0.07) in general population, Buenos 
Aires, Argentina44
Specified panel of anti-CTD has 
been provided in diseased persons, 
mostly with systemic lupus 
erythematosus or has been detected 
by other than FEIA45,46. Also, since 
particular ANA are not specific to 
just one disease, the prevalence of 
ANAs in disease-free individuals 
and particular CTD in general 
population relate reasonably.
33.7% Patients with lupus erythematosus, Brazil NA
47
 Anti-SS-B/La
0.1% (0.0–0.7) Immune-mediated disease-free adults, Estonia FEIA*
Mild Sjögren´s syndrome43
36% Primary Sjögren´s syndrome, Italy ELISA48
 Anti-SS-A/Ro
0.7% (0.3–1.5) Immune-mediated disease-free adults, Estonia FEIA*
Vasculitis and nephritis of CTD, Sjögren´s 
syndrome43
1.9% (0–6.0) General population, Denmark IIF49
68% Patients with primary Sjögren´s syndrome, Italy ELISA
48
SS-A/SS-B 16.5%
Disease-free individuals with 
HLA-DR3 or/and DR11 allele and 




0.0% Immune-mediated disease-free adults, Estonia FEIA*
Lupus erythematosus50
0–45% Patients with lupus erythematosus, Hong Kong, China ELISA
50
 Anti-U1RNP
0.1% (0.0–0.7) Immune-mediated disease-free adults, Estonia FEIA* Mixed connective tissue disease and mild 
Sjögren´s syndrome43
0–84% Patients with lupus erythematosus, Hong Kong, China ELISA
50
 Anti-CENP 0.3% (0.1–1.0) Immune-mediated disease-free adults, Estonia FEIA*
CREST (calcinosis, Raynaud’s, oesophageal 
dysmotility, sclerodactyly, and telangiectasia) 
syndrome 43
 Anti-Jo-1 0% Immune-mediated disease-free adults, Estonia FEIA* Pulmonary fibrosis and poor prognosis of CTD
43
 Anti-Scl-70 0% Immune-mediated disease-free adults, Estonia FEIA* Pulmonary fibrosis and poor prognosis of CTD
43
 GADA






ELISA* Insulin dependent diabetes mellitus: Reported in 
0.4% (0.3–0.4) of general population, Estonia17  
Reported and estimated 1.1–9% in general 
population, Europe51  
Type 1 diabetes:  
Estimated in 0.6–0.8% of general population, 
Europe51  
Latent autoimmune diabetes of adults:  
Estimated in 0.5–0.7% of general population, 
Europe52
GADA in disease-free individuals 
reflect the prevalence of 
autoimmune diabetes in general 
population. Calcium treatment 
of plasma has been suggested 
prior to detection GADA from 
EDTA-plasma11, but may still be 
unsuitable for detecting GADA 
by ELISA. Alternatively, higher 
cut-off values may suit for GADA 
ELISA from plasma, leaving out 
GADA with low affinity and 
insignificance53.














0.9% General population, Southern Spain NA16
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and 2.31, p = 0.054, respectively, compared to the youngest group, 18–26 years of age), (ii) the odds were higher 
if a man consumed alcohol regularly (adOR = 3.33, p = 0.004 compared to non-consumers), and required cardi-
ovascular treatment (adOR = 2.31, p = 0.011). The age adjusted and gender stratified model for women revealed 
that women were less likely positive for tissue non-specific autoantibodies in case of active ovarian hormones 
(adOR = 0.45, p = 0.036 for women who were either menstruating or were receiving HRT compared to women in 
menopause and not receiving HRT) (Fig. 1).
The most prevalent autoantibody GADA was detected in 8.8% of individuals of disease-free population, if the 
cut-off value for GADA positivity was selected > 5 U/ml. However, a proportion of individuals were tested GADA 
greater than 10, 30 or even 50 U/ml (Table 6). Multivariate logistic regression analyses revealed that women with 
positive anti-CTD IgG test were associated with increased chance for GADA > 10 U/ml and > 30 U/ml (adORs 
4.27, p = 0.017 and 5.65, p = 0.047, respectively) when the model was controlled by the ovarian hormonal activity. 
At the same time, active ovarian hormonal status decreased the likelihood of GADA > 10 U/ml and > 30 U/ml 
(adORs 0.34, p = 0.027, and 0.17, p = 0.038, respectively). The results were similar, if models were adjusted by the 
age of older and younger than 45 years instead of hormonal activity (data not shown). The age 45 was selected to 
unify data presentation between men and women. These results suggest that finding of either high level of GADA 
or anti-CTD IgG in disease-free women may reflect preclinical stage of immune-mediated disease, but the onset 
of clinical disease may be postponed by active ovarian hormonal status.
Age adjusted and gender stratified model for men revealed that GADA (> 5 U/ml) coexisted more likely 
with anti-TPO IgG low level (60–100 U/ml) when statistical analyses was controlled by age over 45 years 
(adOR = 12.18, p = 0.015). Similarly, GADA > 30 U/ml coexisted more likely with anti-TPO IgG high level 
(> 100 U/ml, adOR = 22.11, p = 0.003), when controlled by age. The presence of GADA > 10 U/ml showed associ-
ation with age over 45 years in men (adOR = 4.14, p = 0.010 when adjusted for the presence of anti-CTD IgG, and 
adOR = 3.82, p = 0.015 when adjusted for anti-TPO IgG). These results suggest that finding of anti-TPO IgG or 
GADA, regardless of level may reflect activation of adverse immune reaction which aggravates with age in men.
Discussion
The data here represent a cross-sectional study of the prevalence of (auto)immune-mediated diseases in the 
general population of Estonia and the prevalence and association of 6 clinically significant autoantibodies in 
994 (auto)immune-disease-free individuals from the general population. Most importantly, the prevalence of 
anti-TPO IgG and 5 tissue non-specific autoantibodies, anti-tTG IgG, and IgA, anti-CCP IgG, anti-CTD IgG, and 
GADA, in disease-free individuals was 23.6%. This was comparable to the prevalence of (auto)immune-mediated 
diseases registered in the general population of Estonia. In addition, several phenotypic parameters were associ-
ated with the presence of autoantibodies. These associations were gender specific and distinct for anti-TPO and 
tissue non-specific autoantibodies.
The surveying of a population-based registry of 51,862 individuals revealed that a third of the Estonian 
adult population had been diagnosed with some type of (auto)immune-mediated disease. The list of (auto)
immune-mediated diseases was selected to include most diseases’ locations in the body and covered 90 
Autoantibody
Corresponding disease and its prevalence % 
(95% CI) CommentsName
Prevalence % 
(95% CI) Population Method
Anti-TPO IgG
7.2% (5.7–9.1) Immune-mediated disease-free individuals, Estonia FEIA*
Hypo- and hyperthyroidism: Reported in 2.2% 
(2.1–2.3) of general population, Estonia* and 
in 5% of women population, California, USA54 
Hypothyroidism: Screened in 12% of complaint-
free individuals, but reported in < 2% of general 
population, Michigan, USA55
Anti-TPO prevalence in disease-
free individuals seems to be 
comparable to the estimated 
prevalence of thyroid diseases in 
general population but higher than 
reported cases. Thyroid diseases are 
underdiagnosed.
3.3% Disease-free children and adolescents, Leipzig, Germany ECLIA
56
10% (5–15) General population, Denmark Plasma RIA49
8.6% General population, Australia ELISA19
10.7%(8.2–13.9) Immune-mediated disease-free women, Estonia FEIA*




0.6% (0.2–1.4) Immune-mediated disease-free adults, Estonia
FEIA and 
ELISA*
Thyrogastric autoimmune disease58: 17.8% of 
type 1 diabetes patients had anti-TPO, Turkey59
Taken the prevalence of type 
1 diabetes51, the calculated co-
existence of anti-TPO and GADA 
in Turkey59 is lower than detected 
among disease-free individuals 
in Estonia*. The prevalence of co-
existence of these autoantibodies is 
likely population-specific.
0.11–0.14% Patients with type 1 diabetes and anti-TPO, Turkey ELISA
59
Table 4.  Extended commented presentation of autoantibody prevalence of current study and from 
literature data. ANA – antinuclear autoantibodies, ACLIA – electroluminescence assay, ELISA – enzyme 
linked immunosorbent assay, CTD – connective tissue diseases, CCP - cyclic citrullinated peptide, CENP - 
centromere protein, dsDNA - double stranded deoxyribonucleic acid, FEIA - fluoro-enzyme immunoassay, 
GADA - autoantibodies against glutamic acid decarboxylase (molecular weight 65 kDa), IIF – indirect 
immunofluorescent test, Jo-1 - histidyl tRNA synthetize, NA – not available, RIA – radioimmunoassay, SS-A/
Ro - Sjögren’s syndrome type A antigen, SS-B/La - Sjögren’s syndrome type B antigen, Scl-70 - scleroderma-
associated autoantigen of 70 kDa, Sm - Smith protein, TPO – thyroid peroxidase, tTG - tissue transglutaminase, 
U1RNP - ribonucleoprotein U1. *Current article by Haller-Kikkatalo K., Alnek K., Metsküla K., Kisand K., 
Pisarev H., Salumets A., Uibo R.
www.nature.com/scientificreports/
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ICD-10 categories (Supplementary Table S.1). Overall, men were diagnosed less frequently than women; 26.4% 
of men and 32.1% of women had at least one diagnosis (Table 1). Data indicating the prevalence of so many 
immune-mediated diseases in a population is rarely available in the scientific literature, which makes this study 
unique. According to one previous study, subjects with chronic diseases account for one-third of the general pop-
ulation in Germany2, although the list of studied diseases was different from that in this study.
The prevalence of disease was high, as was the prevalence of at least 1 of 6 autoantibodies in the population 
of disease-free individuals, especially among women (diseases occurred in 32.1% (31.6–32.6) of women in the 
general population and autoantibodies were present in 29.4% (25.5–33.6) of diseases-free women (proportion 
test, p > 0.05). Autoantibodies measured here in healthy individuals are presented with previously published 
data in Table 4. The prevalence of anti-tTG IgA, anti-CCP IgG, anti-CTD IgG and anti-TPO IgG in our study is 
comparable to the autoantibodies in general population of other countries12–15. The prevalence of GADA16,17 or 
autoantibodies from CTD IgG panel17–20 is not comparable due to differences either in laboratory tests or study 
populations.
Importantly, the autoantibodies detected in this study, anti-tTG IgG and IgA, anti-CTD IgG, GADA, and 
anti-TPO IgG, have diagnostic value for common autoimmune diseases, and at least some of these may play roles 
in disease pathogenesis. Although autoantibodies were assessed in healthy individuals, the positive cut-off value 
for each autoantibody test was chosen to match the level used to diagnose the corresponding autoimmune dis-
ease. Logically, it could be hypothesized that the group of seropositive but healthy individuals will develop auto-
immune diseases, and the presence of autoantibodies is prognostic marker that precedes clinical manifestation. 
On the other hand, some of autoantibody-positive, disease-free individuals may never develop clinical disease, 
and the presence of autoantibodies may have no clinical significance for them. Although it is not known which 
of the above scenarios occurs, the current study provides important information. Long-term follow-up would be 
the best way to resolve this question.
In men, the presence of anti-TPO was strongly associated with familial anamnesis of maternal autoimmune 
disease. The same association was not revealed in women, although maternal autoimmune disease was reported 
more often in women than men (16.7% vs. 11.4%). Maternal thyroid disease, in particular, accounted for a 
Phenotypic characteristics1
Association with phenotypic characteristics
≥1 tissue non-specific 
autoantibody6 Anti-TPO
Men Women Men Women
Age at time of study (years) OR = 1.03* OR = 1.01 OR = 1.02 OR = 1.03*
Age groups2 
 18–26 years OR = 1 OR = 1 OR = 1 OR = 1
 27–37 years OR = 2.08# OR = 0.86 OR = 0.67 OR = 1.76
 38–52 years OR = 2.47* OR = 1.21 OR = 1.69 OR = 1.84
 > 52 years OR = 3.39* OR = 1.40 OR = 1.58 OR = 3.88*
Occupation
 Employed adOR = 1 adOR = 1 adOR = 1 adOR = 1
 Pension insurance3 adOR = 2.48 adOR = 0.82 adOR = 0.49 adOR = 2.19
 Student or serviceman adOR = 0.98 adOR = 1.56 adOR = 3.72# adOR = 1.08
 Unemployed4 adOR = 1.64 adOR = 1.10 adOR = 0.46 adOR = 0.99
Frequency of alcohol consumption
 No consumption adOR = 1 adOR = 1 adOR = 1 adOR = 1
 Rare – up to few times per year adOR = 1.74 adOR = 1.31 adOR = 0.62 adOR = 0.81
 Seldom – up to every month adOR = 2.92* adOR = 1.44 adOR = 2.05 adOR = 1.75
 Moderate or frequent – up to every 2nd day adOR = 1.45 adOR = 0.93 adOR = 1.10 adOR = 0.69
Active ovarian hormones5 — adOR = 0.50* — adOR = 0.55
Recently used cardiovascular drugs adOR= 1.85# adOR = 1.19 adOR = 1.12 adOR = 0.85
Maternal autoimmune disease adOR = 0.38 adOR = 1.11 adOR = 5.50* adOR = 1.17
Table 5.  Associations between autoantibodies and phenotypic characteristics. 1Characteristics with any 
association with either anti-TPO or tissue non-specific autoantibodies are presented. 2Age groups were formed 
according to the values of the 1st and 3rd quantiles and median of the age and compared with the youngest group 
(18-26 years). 3Pension insurance includes retired persons and individuals who are unemployed but covered by 
health insurance. 4Unemployed also includes women on childcare leave. 5Women with active ovarian hormones 
includes women who menstruate and women with primary or secondary amenorrhea who are currently receiving 
hormone replacement therapy. 6The presence of at least one of five tissue non-specific autoantibodies (antinuclear 
autoantibodies detected with a connective tissue disease screening test and autoantibodies against glutamic acid 
decarboxylase (molecular weight of 65 kDa), thyroid peroxidase, tissue transglutaminase IgG and IgA, or cyclic 
citrullinated peptide). adOR – adjusted odds ratio. *Statistically significant association (p < 0.05), # statistical 
tendency towards association (0.05 < p < 0.1). Associations between phenotypic characteristics and autoantibody 
prevalence were analysed with logistic regression analyses stratified by gender and adjusted for age.
www.nature.com/scientificreports/
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negligible proportion of maternal autoimmune diseases in our cohort (reported in 4 cases, 1 woman and 3 men). 
Therefore, it seems likely that maternal autoimmunity, not specifically thyroid disease, leads to anti-thyroid auto-
immunity in sons. This mother-to-son inheritance relies on several phenomena. First, the X-chromosome con-
tains immunologically important genes, associated with a variety of autoimmune diseases21. Therefore, because 
male offspring inherit maternal X-chromosome, autoimmune susceptibility may be inherited if the mother is 
affected. Second, an increased frequency of skewed X-chromosome inactivation (XCI) has been found in many 
autoimmune diseases22 and may result from chance or genetic factors23. These sons may inherit the defective 
X-chromosome, which cannot be balanced because of the lack of spare X-chromosome in males, in contrast to the 
case in daughters. In this case, the mechanism of XCI to favour autoimmunity has been attributed to the potential 
escape of X-linked self-antigens in the thymus or other peripheral sites that are involved in tolerance24. However, 
these two explanations do not explain why the thyroid gland is preferentially targeted in sons of mothers suffering 
from autoimmune diseases. The third possible explanation involves maternal microchimerism, which has been 
detected in the newborn thyroid gland25. Regardless of the reason for anti-TPO antibodies in male participants, 
anti-TPO IgG can activate complement and cause damage to thyroid cells via antibody dependent cell cytotox-
icity13 eventually leading to thyroid disease. Accordingly, men with anti-thyroid autoantibodies have a 5 times 
greater risk of progressing to overt thyroid gland disease than women6. Indeed, women may be protected from 
autoimmune diseases until menopause, because active ovarian hormones postpone the production of anti-TPO 
and tissue non-specific autoantibodies in women26.
Multivariate association analyses detected several phenotypic associations, suggesting the presence of at least 
one tissue non-specific autoantibody associated with moderate but regular alcohol intake and the need for cardi-
ovascular treatment. These associations were independent of age and they were present in men but not women. 
The impacts of alcohol consumption on health are complex and modulated by several factors such as pattern and 
amount of drinking, genetics, the organ system studied, and the sex and age of the user27. Regular heavy con-
sumption (≥ 3 drinks a day in men) causes suppression of innate immunity28, whereas moderate consumption 
(< 2 drinks a day for men)29 may enhance the effects of vaccines27 and increase intestinal permeability30, which 
can lead to immune recognition of self-antigens31. Here, the effects of alcohol were not considered beneficial, 
since autoantibodies can mark future autoimmunity. Similarly, most of the benefits of moderate alcohol con-
sumption have been described in the context of cardiovascular disease32. Here, we revealed that cardiovascular 
diseases were associated with increased prevalence of tissue non-specific autoantibodies, regardless of whether 
the person was consuming alcohol or not, which has been suggested previously33. Surprisingly, these associations 
were revealed in men and were not significant in women. Since women were tested for risk factors by statistical 
Figure 1. Risk factors for autoantibodies detected in men and women. Autoantibodies against thyroid 
peroxidase (anti-TPO, dashed line) and any tissue non-specific autoantibody (solid line) groups are shown 
separately. The tissue non-specific autoantibody group comprised individuals who tested positive for at least 
one of the 5 tested tissue non-specific autoantibodies. 1age groups were formed according to the values of 1st 
and 3rd quantiles and the median age compared to the youngest group (18–26 years); 2the presence of maternal 
autoimmune disease compared to individuals without maternal autoimmune disease; 3individuals with an 
occupational status of unemployed but being covered by pension insurance (includes retired individuals and 
unemployed individuals with insurance for disability) compared to employed persons; 4seldom but regular 
alcohol consumption (once a month) compared to non-consumers; 5the need for cardiovascular treatment 
on a regular basis at least 2 months prior to the study; 6women with active ovarian hormones includes women 
who menstruate and women with primary or secondary amenorrhea who receive hormone replacement 
therapy compared to women in menopause. Association values are given as odds ratios considered for multiple 
comparisons from multivariate logistic regression models stratified by gender and adjusted for the following 
confounders selected from Table 5: A age groups; B age groups (or ovarian hormonal activity in women), 
maternal autoimmune disease, occupational status, alcohol consumption, cardiovascular treatment. CI –
confidence interval.
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models adjusted for active ovarian hormones, other phenotypic parameters seem less important than ovarian 
hormonal profiles in women.
Childbearing age seemed to be the major protective factor from autoimmune disease in women. Indeed, 
women with active ovarian hormones (either because they were in their fertile years or receiving HRT)12 were 
less likely to be seropositive for anti-TPO and tissue non-specific autoantibodies regardless of confounders. Age 
related protection against autoimmunity can be explained by age related acquired X-chromosome loss or mon-
osomy (XCM)14. Because the X-chromosome has immunologically important genes, XCM contributes to the 
speed of development and the number of overlapping autoimmune diseases15. In addition, the X-chromosome 
contains genes that appear to be crucial in the maintenance of physiological sex hormone levels15. Commonly, 
a substantial decline of sex hormone levels in women occurs at menopause. However, female sex hormones 
have various immunomodulatory effects26. These factors may explain why women were found to be likely 
autoantibody-positive in this study.
In conclusion, approximately one-third of the adult population of Estonia, individuals who lacked (auto)
immune-mediated diseases, tested positive for at least one of six clinically significant autoantibodies. At the same 
time, the documented prevalence of the corresponding (auto)immune-mediated diseases in the general popula-
tion was also one-third. However, some of these diseases, including thyroid disease and coeliac disease, were diag-
nosed less frequently than estimated. The results suggest that the presence of tissue non-specific autoantibodies 
may serve as prognostic markers for future diseases in currently disease-free individuals. The presence of autoan-
tibodies in men depends on general health, age or health manners. In contrast, the protection of active ovarian 
hormones in women decrease any putative risk of health parameters studied here. Different from anti-TPO IgG in 
women, incidental finding of anti-TPO IgG in men with positive familial anamnesis of maternal autoimmune dis-
ease deserves further medical intention. The wider implications of these findings suggest that physicians should 
be encouraged to look for autoimmune markers in addition to treating a variety of patient health complaints.
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